Corcept Therapeutics (CORT) EBT Margin (2012 - 2026)
Corcept Therapeutics (CORT) posted EBT Margin of 17.93% for Q2 2026, up 166.13% sequentially from 27.12% in Q1 2026, and up 163.0% YoY from 6.82% in Q2 2025.
Corcept Therapeutics (CORT) EBT Margin (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported EBT Margin for 15 years, with the latest figure at 17.93% in Q2 2026.
- Quarterly EBT Margin rose 163.0% year-over-year to 17.93% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3.17% (down 1445.0% YoY) and the FY2025 annual result came in at 8.73%, down 1519.0% from the prior year.
- EBT Margin grew to 17.93% in Q2 2026 per CORT's latest filing, from 27.12% in the prior quarter.
- Over five years, EBT Margin peaked at 32.44% in Q3 2022 and troughed at 27.12% in Q1 2026.
- A 5-year average of 18.83% and a median of 23.7% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2026: EBT Margin jumped 639 bps in 2024, then plunged 3323 bps in 2026.
- Over 5 years, EBT Margin stood at 23.56% in 2022, then rose by 15 bps to 27.18% in 2023, then tumbled by 35 bps to 17.57% in 2024, then sank by 72 bps to 4.9% in 2025, then soared by 266 bps to 17.93% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 17.93%, 27.12%, and 4.9% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 17.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.93% |
| Mar 31, 2026 | -27.12% |
| Dec 31, 2025 | 4.90% |
| Sep 30, 2025 | 7.34% |
| Jun 30, 2025 | 16.30% |
| Mar 31, 2025 | 6.12% |
| Dec 31, 2024 | 17.57% |
| Sep 30, 2024 | 29.00% |
| Jun 30, 2024 | 25.40% |
| Mar 31, 2024 | 23.84% |
| Dec 31, 2023 | 27.18% |
| Sep 30, 2023 | 29.44% |
| Jun 30, 2023 | 27.97% |
| Mar 31, 2023 | 17.45% |
| Dec 31, 2022 | 23.56% |
| Sep 30, 2022 | 32.44% |
| Jun 30, 2022 | 31.01% |
| Mar 31, 2022 | 28.66% |
| Dec 31, 2021 | 37.17% |
| Sep 30, 2021 | 37.77% |